✦ LIBER ✦

Safety, Tolerability and Pharmacokinetics of CTP-499 in a Multi-Center, Double-Blind, Two-Arm, Placebo-Controlled, Randomized Study in Non-Dialysis Patients With Stage 3 Chronic Kidney Disease

Book ID: 114470907
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 211 KB
Volume: 59
Category: Article
ISSN: 0272-6386
DOI: 10.1053/j.ajkd.2012.02.102

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease

✍ Karthik Ananthasubramaniam; Robert Weiss; Bruce McNutt; Barbara Klauke; Kathleen 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 333 KB

A Meta-Analysis of Two Double-Blind, Pla

A Meta-Analysis of Two Double-Blind, Placebo Controlled, Randomized Trials to Evaluate the Efficacy and Safety of Carvedilol Treatment in Non-Dialysis Dependent Chronic Kidney Disease Patients with Symptomatic or Asymptomatic Systolic Heart Failure

✍ R. Wali; M. Iyengar; D. Chartyan; M.A. Lukas; C. Cooper; A. Cheung 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 166 KB

46 A Phase 2a Randomized Placebo-Control

46 A Phase 2a Randomized Placebo-Controlled Double-Blind Multi-Center Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Patients With Moderately Active Ulcerative Colitis

✍ Severine Vermeire; Paul J. Rutgeerts; Geert R. D'Haens; Martine De Vos; Brian Br 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 47 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre

A phase 3, randomized, double-blind, pla

A phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in patients with Gaucher disease type 1 (ENGAGE): Results after 9months of treatment

✍ Mistry, Pramod; Lukina, Elena; Dridi, Marie-Françoise Ben; Amato, Dominick; Bari 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 77 KB

Changes in fibroblast growth factor 23 l

Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial

✍ Ureña-Torres, Pablo; Prié, Dominique; Keddad, Karim; Preston, Peter; Wilde, Paul 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 220 KB